Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

DSpace Repository

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

Author: Navid, Fariba; Sondel, Paul M.; Barfield, Raymond; Shulkin, Barry L.; Kaufman, Robert A.; Allay, Jim A.; Gan, Jacek; Hutson, Paul; Seo, Songwon; Kim, KyungMann; Goldberg, Jacob; Hank, Jacquelyn A.; Billups, Catherine A.; Wu, Jianrong; Furman, Wayne L.; McGregor, Lisa M.; Otto, Mario; Gillies, Stephen D.; Handgretinger, Rupert; Santana, Victor M.
Tübinger Autor(en):
Handgretinger, Rupert
Published in: Journal of Clinical Oncology (2014), Bd. 32, H. 14, S. 1445-
Verlagsangabe: Amer Soc Clinical Oncology
Language: English
Full text: http://dx.doi.org/10.1200/JCO.2013.50.4423
ISSN: 0732-183X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)